IRLAB Therapeutics AB Class A (0GFH) Ratios
IRLAB Therapeutics AB Class A Ratios
GB:0GFH's free cash flow for Q2 2026 was $-13.45M. For the 2026 fiscal year, GB:0GFH's free cash flow was increased by $0.00 and operating cash flow was $-13.45M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.80 | 0.80 | 3.36 | 8.31 | 6.07 |
| Quick Ratio | 0.80 | 0.80 | 3.36 | 8.19 | 6.04 |
| Cash Ratio | 0.76 | 0.67 | 3.03 | 7.82 | 5.79 |
| Solvency Ratio | -0.98 | -0.76 | -2.83 | -3.37 | 0.75 |
| Operating Cash Flow Ratio | -0.51 | -0.66 | -4.49 | -4.41 | 1.85 |
| Short-Term Operating Cash Flow Coverage | -2.09 | -1.23 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -21.62M | $ -24.02M | $ 62.23M | $ 235.96M | $ 348.47M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.22 | 0.44 | 0.16 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.98 | 1.85 | 0.24 | 0.01 | 0.02 |
| Debt-to-Capital Ratio | 0.49 | 0.65 | 0.19 | 0.01 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 |
| Financial Leverage Ratio | 4.50 | 4.17 | 1.53 | 1.11 | 1.18 |
| Debt Service Coverage Ratio | -1.98 | -1.06 | -870.97 | -370.11 | 149.79 |
| Interest Coverage Ratio | -5.13 | -7.17 | -908.37 | -380.84 | 142.10 |
| Debt to Market Cap | 0.20 | 0.10 | 0.05 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.72 | 1.37 | 0.54 | 0.08 | 0.13 |
| Net Debt to EBITDA | 0.59 | 0.10 | 0.48 | 2.28 | -7.09 |
| Profitability Margins | |||||
| Gross Profit Margin | -160.71% | -97.67% | -2161.57% | -181.94% | 81.19% |
| EBIT Margin | -160.71% | -76.78% | -3128.58% | -185.01% | 25.30% |
| EBITDA Margin | -153.20% | -71.93% | -3052.55% | -178.50% | 26.85% |
| Operating Profit Margin | -160.71% | -79.38% | -3183.60% | -185.01% | 25.30% |
| Pretax Profit Margin | -191.45% | -87.85% | -3132.07% | -185.50% | 24.92% |
| Net Profit Margin | -191.45% | -87.85% | -3132.07% | -186.80% | 24.92% |
| Continuous Operations Profit Margin | -191.45% | -87.85% | -3132.07% | -185.50% | 24.92% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.70% | 100.00% |
| EBT Per EBIT | 119.13% | 110.67% | 98.38% | 100.26% | 98.49% |
| Return on Assets (ROA) | -79.60% | -61.03% | -100.41% | -35.30% | 10.96% |
| Return on Equity (ROE) | -358.13% | -254.73% | -153.62% | -39.27% | 12.96% |
| Return on Capital Employed (ROCE) | -300.63% | -207.66% | -128.76% | -38.84% | 13.04% |
| Return on Invested Capital (ROIC) | -152.21% | -80.72% | -126.12% | -38.37% | 12.85% |
| Return on Tangible Assets | -120.43% | -93.04% | -136.53% | -41.27% | 12.05% |
| Earnings Yield | -83.35% | -14.91% | -38.96% | -5.75% | 2.27% |
| Efficiency Ratios | |||||
| Receivables Turnover | 14.31 | 4.59 | 0.63 | 5.00 | 12.20 |
| Payables Turnover | 1.93 | 18.82 | 12.20 | 17.18 | 3.18 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 46.69 | 15.58 |
| Fixed Asset Turnover | 10.50 | 9.66 | 0.85 | 7.63 | 24.89 |
| Asset Turnover | 0.42 | 0.69 | 0.03 | 0.19 | 0.44 |
| Working Capital Turnover Ratio | -2.73 | 2.85 | 0.04 | 0.21 | 0.68 |
| Cash Conversion Cycle | -163.41 | 60.16 | 546.26 | 59.52 | -61.52 |
| Days of Sales Outstanding | 25.50 | 79.56 | 576.17 | 72.94 | 29.92 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 7.82 | 23.43 |
| Days of Payables Outstanding | 188.92 | 19.40 | 29.91 | 21.24 | 114.87 |
| Operating Cycle | 25.50 | 79.56 | 576.17 | 80.76 | 53.35 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.82 | -1.26 | -3.18 | -2.75 | 2.49 |
| Free Cash Flow Per Share | -0.82 | -1.27 | -3.18 | -2.82 | 2.47 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -329.60 | -562.63 | -42.24 | 181.70 |
| Capital Expenditure Coverage Ratio | 0.00 | -329.60 | -562.63 | -42.24 | 181.70 |
| Operating Cash Flow Coverage Ratio | -1.84 | -1.09 | -5.98 | -35.87 | 19.49 |
| Operating Cash Flow to Sales Ratio | -0.96 | -0.69 | -29.03 | -2.33 | 0.62 |
| Free Cash Flow Yield | -41.84% | -11.80% | -36.18% | -7.35% | 5.62% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.20 | -6.72 | -2.57 | -17.38 | 43.97 |
| Price-to-Sales (P/S) Ratio | 2.30 | 5.89 | 80.39 | 32.47 | 10.96 |
| Price-to-Book (P/B) Ratio | 4.30 | 17.09 | 3.94 | 6.83 | 5.70 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.39 | -8.48 | -2.76 | -13.60 | 17.80 |
| Price-to-Operating Cash Flow Ratio | -2.39 | -8.50 | -2.77 | -13.92 | 17.70 |
| Price-to-Earnings Growth (PEG) Ratio | -0.48 | 0.13 | -0.05 | 0.05 | -0.29 |
| Enterprise Value Multiple | -0.91 | -8.10 | -2.15 | -15.91 | 33.73 |
| Enterprise Value | 80.08M | 551.09M | 372.70M | 1.74B | 1.88B |
| EV to EBITDA | -0.91 | -8.10 | -2.15 | -15.91 | 33.73 |
| EV to Sales | 1.39 | 5.82 | 65.64 | 28.40 | 9.06 |
| EV to Free Cash Flow | -1.45 | -8.38 | -2.26 | -11.89 | 14.71 |
| EV to Operating Cash Flow | -1.45 | -8.40 | -2.26 | -12.18 | 14.63 |
| Tangible Book Value Per Share | -0.24 | -0.27 | 1.33 | 4.71 | 6.90 |
| Shareholders’ Equity Per Share | 0.46 | 0.63 | 2.23 | 5.61 | 7.72 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | -0.01 | 0.01 |
| Revenue Per Share | 0.86 | 1.82 | 0.11 | 1.18 | 4.02 |
| Net Income Per Share | -1.64 | -1.60 | -3.43 | -2.20 | 1.00 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.01 | 1.00 |
| Interest Burden | 1.19 | 1.14 | 1.00 | 1.00 | 0.98 |
| Research & Development to Revenue | 2.28 | 1.73 | 26.65 | 2.39 | 0.19 |
| SG&A to Revenue | -2.28 | -1.73 | 0.00 | 2.06 | 0.39 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.50 | 0.79 | 0.93 | 1.26 | 2.45 |
Currency in SEK
